Novo's Wegovy cuts BMI in kids as young as 6, full trial results show
Novo Nordisk published full late-stage trial results Monday showing Wegovy cut BMI in children ages 6 to under 12 with obesity. More than 40% of treated kids were no longer classified as obese at 68 weeks, with no new safety flags. No obesity drug is approved yet for under-12s.
- 2 sources report it: cnbc.com, breakingthenews.net.
- The source published it on Nov 16, 2026 at 3:00 PM.
Nothing open. Every check passed.
Novo Nordisk rolled out the full results Monday from a late-stage trial showing its Wegovy injection helped children ages 6 to under 12 with obesity shed weight and significantly lower their body mass index. Wegovy cut BMI by an estimated 19.7 percentage points on average compared with placebo at 68 weeks, with BMI dropping 17.4% in kids on the drug and climbing 2.2% on placebo. Those figures assume patients stayed on treatment through the trial.
Counting every child in the study, including those who quit treatment, Wegovy still beat placebo, lowering BMI by an estimated average of 16.2 percentage points at 68 weeks. All 167 kids also got lifestyle modifications throughout, including a reduced-calorie diet and more physical activity. More than 40% of Wegovy-treated children were no longer classified as having obesity after 68 weeks, a result Novo first shared in September.
The disease burden here is heavy and young. In the trial, 85% of children started with moderate to severe obesity, corresponding to BMI thresholds of 35 and above and 40 or higher, and nearly half already had at least one obesity-related complication such as high blood pressure, high cholesterol or sleep apnea. Dr. Andrea Traina, Novo's medical director lead of obesity, called it a very significant disease burden in this very young patient population.
On safety, Novo said Wegovy's overall safety and tolerability in children tracked what was seen in adult trials, and that it observed no safety concerns related to growth or pubertal development. The market is vast: the World Obesity Federation estimates the disease affected roughly 177 million children and teens ages 5 to 19 worldwide in 2025, a figure projected to reach 228 million by 2040. Wegovy is already approved for obesity in kids 12 and older, but nothing is approved for those under 12.
One gap stays open. Traina said the two-year study does not establish whether treating obesity earlier changes its long-term trajectory, nor what treatment and maintenance might look like as these children grow into adulthood. She called that an evidence gap, and pointed to the potential of future research.
TopicsNovo Nordisk · Wegovy · Andrea Traina · World Obesity Federation
Written by AI from verified reporting.

